<DOC>
	<DOCNO>NCT00627627</DOCNO>
	<brief_summary>To evaluate antitumor activity follow treatment IPI-504 patient breast cancer .</brief_summary>
	<brief_title>A Study Evaluate Antitumor Activity Safety IPI-504 Patients With Advanced Breast Cancer</brief_title>
	<detailed_description>To evaluate antitumor activity follow treatment IPI-504 patient locally advance metastatic HER2+ breast cancer progress despite prior HER2-targeted therapy .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<criteria>Adult woman least 18 year age time sign Informed Consent Form ; Written inform consent HIPAA authorization ( applies cover entity USA ) obtain patient prior perform studyrelated procedure , include screen visit ; Pathologically confirm breast cancer assessment primary metastatic breast cancer ; Locally advance metastatic breast cancer define T4 primary tumor Stage IIIB/ IIIC disease Stage IV disease , respectively , accord Sixth Edition American Joint Committee Cancer [ AJCC ] TNM System ( Appendix A ) ; Measurable disease accord RECIST lesion accurately measure least one dimension long diameter ³ 20 mm use conventional compute tomography ( CT ) magnetic resonance imaging ( MRI ) scan ³ 10 mm spiral CT scan ; use chest xray encourage , however , may use necessary ; HER2expressing primary metastatic tumor ( Grade 3+ stain intensity [ scale 0 3 ] via IHC assay HER2 amplification fluorescence situ hybridization ) , result recent biopsy take indicative HER2 status ; Progression treatment least 1 3 regimen contain trastuzumab lapatinib ( treatment regimens include trastuzumab lapatinib qualify ) adjuvant , neoadjuvant , locally advanced , metastatic disease either one follow stipulation : 1 . Patients may receive neoadjuvant adjuvant treatment prior trastuzumab lapatinib treatment must demonstrate evidence disease progression &gt; 12 month follow completion therapy ; 2 . Patients receive trastuzumabbased therapy locally advance metastatic disease minimum 9 week duration . Patients may receive 1 trastuzumabbased combination therapy ; Patients receive lapatinibbased therapy locally advance metastatic disease minimum 9 week duration ; Resolution toxic side effect prior chemotherapy , radiotherapy surgical procedure NCI CTCAE Grade ≤ 1 patient 's baseline ; Eastern Cooperative Oncology Group ( ECOG ) performance status 0 2 ( see Appendix B ) ; Life expectancy least 3 month ; Left ventricular ejection fraction &gt; 45 % ; Absolute neutrophil count ( ANC ) ≥ 1,500 cells/mm3 ; platelet count ≥ 100,000 cells/mm3 ; hemoglobin ≥ 9.0 g/dL ( may increase level transfusion long evidence active bleeding ) ; Prothrombin time international normalized ratio within normal range ( unless patient receive anticoagulation therapy ) , PTT within normal range ; AST ALT ≤ 2.5 ´ upper limit normal ( ULN ) ≤ 5 ´ ULN patient liver metastasis ; total bilirubin ≤ 1.5 ´ ULN [ unless due Gilbert 's syndrome ( unconjugated hyperbilirubinemia ) case bilirubin &lt; 3.5mg/dL ) ; hepatic alkaline phosphatase ≤ 2.5 ´ ULN ; Serum creatinine ≤ 1.5 ´ ULN calculate creatinine clearance ≥ 30 mL/min ; Women central nervous system ( CNS ) metastases eligible clinically stable least 3 month discontinuation prior corticosteroid therapy ; Female patient must non childbearing potential use effective contraception , eg , use oral contraceptive additional barrier method ( since study drug may impair effectiveness oral contraceptive ) , double barrier method ( diaphragm spermicidal gel condom contraceptive foam ) , DepoProvera , partner vasectomy , total abstinence , willing continue effective contraception method 30 day last dose IPI504 ; Patients must able adhere study visit schedule protocol requirement . Previous treatment 17AAG , 17DMAG , know Hsp90 inhibitor ; Concurrent radiation surgery therapy ; Treatment breast cancer approve investigational product , include local systemic therapy within 4 week prior first dose IPI504 study ; Initiation discontinuation concurrent medication alters CYP3A activity within 2 week prior treatment IPI504 . Patients stable dose drug know alter CYP3A activity &gt; 2 week eligible enroll ; Presence active infection systemic use antimicrobial within 72 hour prior treatment IPI504 ; Untreated brain metastasis ( patient history brain metastasis eligible long definitive treatment give patient clinically stable least 3 month discontinuation prior corticosteroid therapy ) ; Significant comorbid condition disease judgment Investigator would place patient undue risk interfere study ( eg , cardiac disease acute coronary syndrome unstable angina within 6 month , uncontrolled hypertension , arrhythmia require medication mechanical control , conduction system abnormality leave bundle branch block second degree heart block , cirrhotic liver disease , cerebrovascular accident , condition ) ; Women pregnant lactating ; Sinus bradycardia ( rest heart rate &lt; 50 bpm ) secondary intrinsic conduction system disease ; Patients sinus bradycardia secondary pharmacologic treatment may enroll withdrawal treatment result normalization rest heart rate within normal limit ; Screening QTc &gt; 470 msec , previous history QTc prolongation take medication ; Active recent history ( within 3 month ) keratitis keratoconjunctivitis .</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>February 2010</verification_date>
</DOC>